pharmaphorum November 10, 2023
Phil Taylor

Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne disease.

The French biotech’s VLA1553 vaccine has been cleared under the Ixchiq brand for use in people aged 18 and over who are at increased risk of exposure to chikungunya, which causes fever and debilitating joint pain, as well as muscle aches, joint swelling, headache, nausea, fatigue, and rash. In severe cases, it can cause systemic complications and death.

The FDA said chikungunya – which means “disease that bends up the joints” in the language of the Makonde tribe in Africa – is an emerging global health threat with at least five million cases reported in...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
The Holy Grail of Biology
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations

Share This Article